These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7427980)

  • 21. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Platelet aggregation in whole blood and prostacyclin in hyperlipemia types II and IV].
    Craveri A; Lanfredini M; Citella C; Barbesti S; Tempesta A; Gallo E
    Minerva Med; 1988 May; 79(5):349-54. PubMed ID: 3374826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 24. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dietary treatment of patients with familial hyperlipoproteinemias].
    Solovév EIu; Rozhkova TA; Koshechkin VA; Pogozhaeva AV
    Kardiologiia; 1992; 32(11-12):56-8. PubMed ID: 1297883
    [No Abstract]   [Full Text] [Related]  

  • 26. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effects of avocado on the level of blood lipids in patients with phenotype II and IV dyslipidemias].
    Carranza J; Alvizouri M; Alvarado MR; Chávez F; Gómez M; Herrera JE
    Arch Inst Cardiol Mex; 1995; 65(4):342-8. PubMed ID: 8561655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fatty acid metabolism in primary hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1979 Oct; 34(20):suppl 287-9. PubMed ID: 398634
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Musculoskeletal symptoms in patients with primary hyperlipoproteinemia. A prelimary study].
    Brekke SE; Kogstad OA
    Tidsskr Nor Laegeforen; 1979 Oct; 99(29):1444-6. PubMed ID: 516016
    [No Abstract]   [Full Text] [Related]  

  • 32. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
    Crepaldi G; Avogaro P; Descovich GC; Di Perri T; Postiglione A; Sirtori CR; Strano A; Ventura S; Musatti L
    Atherosclerosis; 1988 Mar; 70(1-2):115-21. PubMed ID: 3281679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Levels of high-density lipoprotein cholesterol in persons with hypertrigliceridemia-hyperlipoproteinemia type IV].
    Kusić M; Gavrilović M; Mihajlović M
    Srp Arh Celok Lek; 1982 Jun; 110(6):691-6. PubMed ID: 7170652
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 36. [Dyslipoproteinemia and blood levels of various microelements in patients with hypertension living in the areas of different altitudes and climate].
    Bobokhodzhaev IIa
    Klin Med (Mosk); 1987 Aug; 65(8):38-42. PubMed ID: 2960851
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of lipid-lowering diets on patients with hyperlipoproteinemia.
    Gustafsson IB; Vessby B; Boberg J; Karlström B; Lithell H
    J Am Diet Assoc; 1982 May; 80(5):426-32. PubMed ID: 7076998
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.